Keyphrases
Ertapenem
100%
Enterobacterales
100%
Zidebactam
100%
OXA-48
33%
Klebsiella Pneumoniae (K. pneumoniae)
22%
Metallo
22%
Outpatient Parenteral Antibiotic Therapy
22%
National Reference Laboratory
11%
COVID-19
11%
Escherichia Coli
11%
Antimicrobial Resistance
11%
Carbapenemase-producing
11%
Gram-negative
11%
Study Support
11%
Secondary Care
11%
Nosocomial Pathogens
11%
Agar Dilution
11%
Animal Experiment
11%
Inoculum
11%
Carbapenemases
11%
β-lactamase
11%
Carbapenemase-producing Enterobacterales
11%
Metallo-carbapenemase
11%
MDR E. Coli
11%
Trial Data
11%
Backlog
11%
Acceptable Range
11%
Once-daily Regimen
11%
Elective Procedures
11%
Immunology and Microbiology
Enterobacterales
100%
Minimum Inhibitory Concentration
75%
Escherichia coli
50%
Animal Experiment
50%
Klebsiella pneumoniae
25%
Antimicrobial Resistance
25%
Infectious Agent
25%
Severe Acute Respiratory Syndrome Coronavirus 2
25%
Inoculum
25%
Agar Dilution
25%
Medicine and Dentistry
Ertapenem
100%
Zidebactam
100%
Carbapenemase
33%
Antibiotic Therapy
22%
Escherichia coli
22%
Extended Spectrum Beta Lactamase
22%
Outpatient
22%
Beta-Lactamase
22%
Klebsiella pneumoniae
11%
Infection
11%
Antibiotic Resistance
11%
Severe Acute Respiratory Syndrome Coronavirus 2
11%
Agar
11%
Pathogen
11%
Penicillinase
11%
Pharmacology, Toxicology and Pharmaceutical Science
Ertapenem
100%
Zidebactam
100%
Carbapenemase
33%
Antibiotic Therapy
22%
Escherichia coli
22%
Extended Spectrum Beta Lactamase
22%
Klebsiella pneumoniae
11%
Infection
11%
Infectious Agent
11%
Antimicrobial Resistance
11%
Penicillinase
11%
Agar Dilution
11%
SARS Coronavirus
11%
Antibiotic Resistance
11%